In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...
A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...
Stocktwits on MSN
The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in
Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...
Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...
Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback